AUC

OpenYield Launches Fully Automated, Equity-Like Marketplace to Lead Bond Trading Into the Next Era

Retrieved on: 
Thursday, March 28, 2024
MSRB, Algorithm, ATS, Toronto-Dominion Bank, AUC, Flow Traders, Apex, Human, Capital market, Treasury, API, FINRA, Security (finance)

NEW YORK, March 28, 2024 /PRNewswire/ -- OpenYield Trading LLC, a FINRA-registered broker-dealer and SEC-registered alternative trading system (ATS), today printed its first trade, marking the launch of its platform. OpenYield modernizes fixed-income investing and empowers broker-dealers, advisors and asset managers to easily enter the bond market or enhance their existing offerings. With unique liquidity, no minimums, flexible APIs and a powerful technology stack that delivers data and analytics, OpenYield provides a low-cost, equity-like marketplace for bond trading. 

Key Points: 
  • OpenYield modernizes fixed-income investing and empowers broker-dealers, advisors and asset managers to easily enter the bond market or enhance their existing offerings.
  • With unique liquidity, no minimums, flexible APIs and a powerful technology stack that delivers data and analytics, OpenYield provides a low-cost, equity-like marketplace for bond trading.
  • To date, OpenYield has onboarded prominent algo-enabled market makers such as Flow Traders and TD Securities Automated Trading.
  • We're thrilled to support OpenYield as they pave the way for broker-dealers, advisers, and beyond to enter the bond trading arena seamlessly.

Premier Pediatric Research Center Adopts Complion's eISF Platform to Strengthen Pediatric Research Excellence

Retrieved on: 
Tuesday, March 26, 2024
AUC, ChromeOS, SAN, Factorization of polynomials, Data management, Research, Clinical trial, Clinical data management, Nursing

This collaboration marks a significant milestone, as another of the nation's top 10 pediatric research institutions has chosen Complion's sophisticated eISF system to improve compliance and data management processes across its research endeavors.

Key Points: 
  • This collaboration marks a significant milestone, as another of the nation's top 10 pediatric research institutions has chosen Complion's sophisticated eISF system to improve compliance and data management processes across its research endeavors.
  • As a leading pediatric medical center overseeing almost 150 ongoing studies across its research portfolios, this world-class institution sought an exceptional eClinical solution to meet the demands of its complex pediatric clinical research.
  • Complion was chosen because of its ability to simplify research workflows by converting manual, time-consuming tasks into automated, efficient operations.
  • Complion's eISF system is distinguished by its targeted design, developed to meet the unique requirements of complex pediatric clinical research.

Advanced Map of Human Blood Stem Cells Could Guide Highly Targeted Leukemia Care

Retrieved on: 
Thursday, March 21, 2024
Glycophorin A, B cell, Gene, Flow cytometry, Gene expression, Cell, AML, Mechanics, Patient, Biomarker, Research, RNA, Leukemia, Doctor of Philosophy, AUC, CD326, Antibody, Machine learning, Game theory, Blood, Hematology, Bone marrow, Atlas, Vaccine

CINCINNATI , March 21, 2024 /PRNewswire/ -- Thanks to an unusual application of game theory and machine learning technology, a large team of scientists led by experts at Cincinnati Children's has published the world's most detailed "atlas" of the many types of stem cells and early progenitors involved in producing human blood from diverse donors.

Key Points: 
  • The team has identified more than 80 distinct subsets of hematopoietic stem and progenitor cells (HSPCs) – early-stage cells that kick off production of mature red cells, white cells and other elements of our complex blood system.
  • Among the team's key findings:
    Mixing a new "cocktail" of 132 antibodies that can target surface proteins on HSPCs and related cells.
  • Testing demonstrated that the new mix outperforms commercial products for profiling human bone marrow cells.
  • One of the most immediate potential applications of the new stem cell atlas centers on how treatment centers monitor patients receiving therapies for leukemia.

International Harrington Prize Awarded to Dr. Arlene Sharpe

Retrieved on: 
Tuesday, March 19, 2024
LDL, Human papillomavirus infection, Patient, DSM-IV codes, Lecture, National Cancer Institute, Harvard University, Creativity, AAP, PD-1, Massachusetts General Hospital, Science, Diabetes, Marfan syndrome, All India Mahila Congress, Immunology, AUC, NIH, Cancer, Nivolumab, Immune system, Biochemistry, Harvard Medical School, Cervical cancer, Research, University, Antibody, ASCI, FDA, Mount Sinai Hospital, Sickle cell disease, University of Pennsylvania, PCSK9, COVID-19, Doctor of Philosophy, Biology, Kidney, Thalassemia, Johns Hopkins University, Society, Division, Leptin, Pharmaceutical industry

CLEVELAND, March 19, 2024 /PRNewswire/ -- The eleventh annual Harrington Prize for Innovation in Medicine has been awarded to Arlene H. Sharpe, MD, PhD, Kolokotrones University Professor and Chair of the Department of Immunology at Harvard Medical School. The award recognizes her breakthrough discoveries in immune regulation, which have established foundational principles in immunology and led to new cancer therapies that act by boosting the immune response to cancer.

Key Points: 
  • CLEVELAND, March 19, 2024 /PRNewswire/ -- The eleventh annual Harrington Prize for Innovation in Medicine has been awarded to Arlene H. Sharpe, MD, PhD, Kolokotrones University Professor and Chair of the Department of Immunology at Harvard Medical School.
  • Her work helped identify key pathways that restrain the activity of T lymphocytes (immune cells) to fight cancer.
  • A committee composed of members of the ASCI Council and the Harrington Discovery Institute Scientific Advisory Board reviewed nominations from leading academic medical centers globally before selecting the 2024 Harrington Prize recipient.
  • 2023: Jean Bennett, MD, PhD, and Albert M. Maguire, MD, for their groundbreaking translational research to restore sight in inherited genetic diseases.

Microsoft and NVIDIA announce major integrations to accelerate generative AI for enterprises everywhere

Retrieved on: 
Monday, March 18, 2024
Cloud, Microsoft, Sanofi, Microsoft Azure, GTC, Organization, Natural language processing, GPU, Triton, Broad Institute, Public health, Biotechnology, Mass General Brigham, MIT, InfiniBand, Harvard University, SAN, MIG, 3D, Microsoft Power BI, AI, University, First officer (aviation), Software, GENETICS, AUC, VM, LLM, Cloud computing, VMS, Creativity, NIM, Flywheel, NVIDIA, Health, Mass, Silicon, Video game

New NVIDIA generative AI Microservices for enterprise, developer and healthcare applications coming to Microsoft Azure AI

Key Points: 
  • New NVIDIA generative AI Microservices for enterprise, developer and healthcare applications coming to Microsoft Azure AI
    REDMOND, Wash. and SAN JOSE, Calif., March 18, 2024 /PRNewswire/ -- At GTC on Monday, Microsoft Corp. and NVIDIA expanded their longstanding collaboration with powerful new integrations that leverage the latest NVIDIA generative AI and Omniverse™ technologies across Microsoft Azure, Azure AI services, Microsoft Fabric and Microsoft 365.
  • "AI is transforming our daily lives — opening up a world of new opportunities," said Jensen Huang, founder and CEO of NVIDIA.
  • At NVIDIA GTC , Microsoft is demonstrating a preview of what is possible using Omniverse Cloud APIs on Microsoft Azure.
  • NVIDIA GPUs and NVIDIA Triton Inference Server™ help serve AI inference predictions in Microsoft Copilot for Microsoft 365.

INHALE-3 Study’s Initial Meal Challenge Results Comparing Afrezza® Head-To-Head With Multiple Daily Injections (MDI) and Insulin Pumps

Retrieved on: 
Monday, March 11, 2024
Diabetes, Senior, Randomized controlled trial, Inhalable insulin, RAA, Teaching, Hyperglycemia, MannKind Corporation, AUC, A1C, Standard of care, Conference, ATTD, Safety, University, MDI, Patient, Insulin, Automation, Clinical trial, T1D, Pharmaceutical industry

INHALE-3 is a Phase 4 U.S. clinical trial evaluating inhaled insulin (plus basal) vs. standard of care.

Key Points: 
  • INHALE-3 is a Phase 4 U.S. clinical trial evaluating inhaled insulin (plus basal) vs. standard of care.
  • “In this large, randomized trial utilizing more appropriate dose conversion, we are excited to see meal challenge results support the safety and efficacy of inhaled insulin from the start.”
    INHALE-3 is a 17-week randomized controlled trial with a 13-week extension.
  • Subjects utilizing inhaled insulin received a higher initial conversion dose than in the current label.
  • For the meal challenge, the inhaled insulin group took an inhaled insulin dose immediately prior to a standardized meal (a 240 calorie nutritional shake) whereas those using usual care used RAA 5-15 minutes prior to the meal.

Apogee Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for APG777, its Novel Half-Life Extended Anti-IL-13 Antibody for the Treatment for Atopic Dermatitis and Other Inflammatory Diseases, Exceeding its Trial Objectives Ahead of Sc

Retrieved on: 
Tuesday, March 5, 2024
Paragon, Well, SAD, PD, Injection, I&I, Waldman, Headache, Inflammation, Quality of life, Management, Atopic dermatitis, Asthma, TARC, AUC, Volunteering, Cmax, Chronic obstructive pulmonary disease, Outline of health sciences, Safety, Biomarker, Therapy, CQD, Chronic pain, Immunology, IGA, Webcast, Sleep, Patient, MPH, Half-life, Serum, Pharmaceutical industry

Based on these data, the company plans to initiate a randomized, placebo-controlled, Phase 2 clinical trial in patients with moderate-to-severe AD in the first half of 2024 ahead of schedule.

Key Points: 
  • Based on these data, the company plans to initiate a randomized, placebo-controlled, Phase 2 clinical trial in patients with moderate-to-severe AD in the first half of 2024 ahead of schedule.
  • At Apogee, we refuse to stop at good enough and are dedicated to advancing innovative solutions for patients.
  • The Phase 1 trial is a first-in-human, randomized, double-blind, placebo-controlled study designed to evaluate safety and PK of APG777 in healthy volunteers.
  • A live webcast of the call will be available on the Investor Relations page of Apogee’s website at https://investors.apogeetherapeutics.com/news-events/events .

Spelman College led team awarded a $14 Million National Science Foundation grant focused on transforming the research enterprise

Retrieved on: 
Wednesday, February 21, 2024
HBCU, Economic development, Knowledge management, Collective impact, Research, Morehouse School of Medicine, Spelman College, Entrepreneurship, Education, Clark Atlanta University, Growth, NSF, AUC, Achievement Medal, National Science Foundation, Atlanta University Center, Ideation, Morehouse College, Spelman, Nation, Senate

NSF announced a $20 million investment across eight institutions through its GRANTED initiative, transforming research support access.

Key Points: 
  • NSF announced a $20 million investment across eight institutions through its GRANTED initiative, transforming research support access.
  • Many of the initiatives previously funded by NSF GRANTED have had a transformative impact, particularly for emerging research and minority-serving institutions.
  • "This $20 million investment through NSF's GRANTED initiative reflects our commitment to breaking down barriers in research access.
  • That’s why I partnered with Spelman College and the National Science Foundation to deliver a $14 million investment in the Atlanta University Center to expand its world-class research capabilities.

HeartBeam Receives Two New US Patents for its Core Cardiac Monitoring Technology

Retrieved on: 
Thursday, March 7, 2024
Health Technology, Health, Cardiology, Medical Devices, Doctor of Philosophy, AMI, Physician, Invention, 3D, Patent, AUC, ECG, Splenic infarction, Patient, Curve, Heart, Wrist, Medical device

HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, announced today that it has received two new patents on its core vectorelectrocardiography (VECG) technology from the United States Patent and Trademark Office.

Key Points: 
  • HeartBeam, Inc. (NASDAQ: BEAT), a medical technology company focused on transforming cardiac care through the power of personalized insights, announced today that it has received two new patents on its core vectorelectrocardiography (VECG) technology from the United States Patent and Trademark Office.
  • HeartBeam now has 14 issued and allowed US patents and 4 international patents for its VECG technology which collects 3D signals of the heart and converts them into a 12-lead ECG.
  • For each patient, HeartBeam provides a comparative baseline ECG which aids physicians in gaining richer insights about the patient’s cardiac health.
  • In addition to the 14 issued and allowed US patents and 4 international patents, HeartBeam has 20 pending applications worldwide.

New Data Demonstrate Sunbird Bio’s APEX Diagnostic Test Accurately Differentiates Key Alzheimer’s Disease Biomarker in Blood

Retrieved on: 
Tuesday, March 5, 2024
Mental Health, Research, Neurology, Clinical Trials, Biotechnology, Health, General Health, Other Science, Science, Traffic barrier, EV, System, Blood, Cerebrospinal fluid, Neurological disorder, AUC, Amplification, Conference, Seminal vesicles, Biomarker, Patient, Dementia, DSM-IV codes, CSF, Disease, Diagnosis, PET, APEX, Brain, Medical imaging

The data will be shared this week in a poster presentation at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Disease.

Key Points: 
  • The data will be shared this week in a poster presentation at the AD/PD™ 2024 International Conference on Alzheimer’s and Parkinson’s Disease.
  • “These results provide further evidence that the APEX platform has the potential to offer highly sensitive and accurate Alzheimer’s disease diagnosis equivalent to PET scans from a simple blood draw,” said John McDonough, executive chair and CEO of Sunbird Bio.
  • The APEX Aβ test is a blood-based diagnostic that uniquely detects very low levels of disease-specific proteins in blood with high accuracy.
  • EV-associated Aβ in blood are highly correlative and a direct reflection of Aβ build-up in the brain, a key abnormality in Alzheimer’s disease.